Semaglutide
BRANDS Ozempic · Wegovy · Rybelsus
Last reviewed 2026-10-30
Our read Opinion
An established prescription therapy with multiple outcome-based indications. Compounded versions are not FDA-approved or interchangeable with approved products.
- Type
- FDA-approved
- Regulatory status
- FDA-approved (Ozempic, Rybelsus, Wegovy)
- Compounding status
- Approved product (not applicable)
- FDA-approved indications
- Product-specific: type 2 diabetes; chronic weight management in eligible adults and adolescents; cardiovascular risk reduction in eligible adults; kidney/CV risk reduction in adults with type 2 diabetes and CKD; noncirrhotic MASH with F2-F3 fibrosis in adults (accelerated approval).
- Evidence level
- Human RCTs (approved use)
- Routes studied
- Injection, Oral
- WADA
- Not prohibited
- Developer
- Novo Nordisk
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Reported to lower blood glucose
- —Reported to reduce body weight in large trials
GLP-1 receptor agonist that increases glucose-dependent insulin secretion, reduces glucagon and food intake, and delays gastric emptying.
FDA-approved semaglutide products have formulation-specific diabetes, weight-management and risk-reduction indications. Wegovy injection also has accelerated approval for specified noncirrhotic MASH; approval does not extend to research preparations.
Statuses change; check the linked primary source.
Momentum Opinion
Steady
1 news items in last 30 days
Strong evidence supports specific clinical uses, not blanket longevity claims. Keep approved products distinct from compounded or research preparations.
Reuters
A label expansion is under review based on cardiovascular outcomes data.
More weight loss than semaglutide alone by adding an amylin signal for fullness.
Lose fat on a GLP-1 while holding on to muscle.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.